Cell Therapy for Critical Care Indications

Abstract: MultiStem® is an allogeneic adult bone marrow derived stem cell product, for the treatment of diseases and conditions in the neurological, inflammatory and immune, and cardiovascular disease areas, as well as other indications. Pre-clinical studies demonstrate that MutiStem cells interact with endogenous host cells to modulate the response to inflammation and immune dysregulation. Athersys is currently conducting several clinical trials in the acute care setting including acute ischemic stroke, trauma and COVID-19 induced acute respiratory disease syndrome.

Dr. Anthony Ting is the Vice President of Regenerative Medicine and Head of Cardiopulmonary Programs at Athersys. His expertise is in translational clinical studies with adult stem cell therapies and he has been responsible for all stages for the development of MultiStem® from the bench to the bedside. Dr. Ting was a Principal Investigator at the Institute of Molecular and Cell Biology (IMCB) at the National University of Singapore. Prior to joining IMCB, he was a post-doctoral fellow at Stanford University, and he received his Ph.D. in Cell Biology from Johns Hopkins University.

Thursday, November 12, 2020

11:00 a.m. – 12:15 p.m.

Virtual Seminar:
Zoom: https://uark.zoom.us/j/86880884478?pwd=NFiVdUTVa5MWtpWnNBb2syV2pGQT09